OncoMatch/Clinical Trials/NCT05412589
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
Is NCT05412589 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies mFOLFOX7+Camrelizumab+Apatinib for stage iii hepatocellular cancer (cnlc staging).
Treatment: mFOLFOX7+Camrelizumab+Apatinib — This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immunotherapy
Have received immunotherapeutic drugs or interferon in the past.
Cannot have received: first-line drugs such as Sorafenib (Sorafenib)
Did not received any type of other first-line drugs such as Sorafenib
Lab requirements
Blood counts
White blood cells count ≥3.0×10^9/L; Platelet count ≥70×10^9/L; Hemoglobin ≥80g/L
Kidney function
Serum creatinine (SCr) ≤ 1.5x ULN or creatinine clearance ≥50 ml/min (Cockcroft-Gault formula)
Liver function
Child-pugh liver function grading: Grade A or B; Total bilirubin (TBIL) ≤ 1.5x ULN; AST or ALT ≤ 3x ULN
The function of vital organs meets the following requirements...Blood routine: White blood cells count ≥3.0×10^9/L Platelet count ≥70×10^9/L Hemoglobin ≥80g/L; Liver and kidney function: Serum creatinine (SCr) ≤ 1.5x ULN or creatinine clearance ≥50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) ≤ 1.5x ULN; AST or ALT ≤ 3x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify